Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesJazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
234.66 USD 4.92 ( 2.14%)
Last update at 2026-11-04T21:00:00Z
VOLUME
896275
Market Cap
15633.38M
P/E
16.83

Momentum Score

…

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
228.45
Low
234.66
High
52 Week Price Range
125.79
Low
266.38
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Jazz Pharmaceuticals is a global specialty biopharmaceutical company developing and commercializing treatments in neuroscience and oncology, including marketed medicines for sleep disorders and hematologic cancers. Long-term growth may be supported by uptake of newer formulations, international expansion, pipeline progress and selective acquisitions, making the firm notable for its recurring specialty-product revenue.
Principal risks are patent expirations and generic competition, regulatory or clinical setbacks, pricing and reimbursement pressure, and integration/execution risk.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
229.74
Dividend Yield
-
Revenue TTM
4601.29M
Revenue Per Share
74.60
Gross Profit TTM
4203.44M
Debt / Equity
1.26
ROE
22.11%
Net Debt
4031.97M
ROCE
-4.60%
Diluted EPS TTM
14.31

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -628.59M 468.69M 294.92M -372.78M -112.84M
Net income -356.15M 560.12M 414.83M -214.14M -328.95M
Selling general administrative 1809.27M 1385.29M 1330.27M 1416.97M 1451.68M
Gross profit 3764.29M 3623.24M 3398.63M 3118.86M 2653.48M
Reconciled depreciation 696.30M 660.07M 624.23M 629.47M 552.48M
Ebit -433.54M 861.64M 810.73M 512.27M 170.28M
Ebitda 108.46M 1521.71M 1449.42M 1111.44M 696.05M
Depreciation and amortization 542.00M 660.07M 638.70M 599.17M 525.77M
Non operating income net other - - - -28.93M -5.06M
Operating income 224.42M 716.63M 578.58M 512.27M 170.28M
Other operating expenses 4043.16M 3352.32M 3255.62M 3147.11M 2923.96M
Interest expense 195.05M 238.10M 289.44M 288.24M 278.77M
Tax provision -272.44M -91.43M -186.87M -158.65M 216.12M
Net interest income -195.05M -238.10M -293.24M -288.24M -278.77M
Non recurring - - - 577.80M -
Income tax expense -272.44M -91.43M -119.91M -158.65M 216.12M
Total revenue 4267.59M 4068.95M 3834.20M 3659.37M 3094.24M
Total operating expenses 3539.87M 2906.61M 2820.05M 2606.59M 2483.20M
Cost of revenue 503.30M 445.71M 435.58M 540.52M 440.76M
Total other income expense net -853.01M -247.94M -283.66M -885.05M -283.12M
Net income from continuing ops -356.15M 560.12M 79.95M -214.14M -329.67M
Net income applicable to common shares - - - -224.06M -329.67M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 11659.34M 12012.26M 11393.36M 10835.25M 12298.64M
Intangible assets 4429.51M 4755.69M 5418.04M 5794.44M 7152.33M
Other current assets 476.43M 438.95M 334.78M 267.19M 252.39M
Total liab 7340.76M 7918.50M 7656.36M 7749.52M 8333.45M
Total stockholder equity 4318.58M 4093.76M 3737.00M 3085.73M 3965.19M
Deferred long term liab - - - 944.34M 12.03M
Other current liab 1019.45M 896.17M 774.47M 810.97M 675.91M
Common stock 0.01M 0.06M 0.06M 0.06M 0.06M
Capital stock 0.06M 0.06M 0.06M 0.06M 0.06M
Retained earnings 646.18M 1127.35M 878.66M 733.59M 830.23M
Other liab - - - 1045.94M 1418.00M
Good will 1829.34M 1716.32M 1753.13M 1692.66M 1827.61M
Other assets - - - 435.14M 363.94M
Cash 1391.90M 2412.86M 1206.31M 881.48M 591.45M
Total current liabilities 2242.52M 1038.57M 1536.69M 933.19M 809.30M
Current deferred revenue - - 35.07M 0.46M 2.09M
Net debt 4031.97M 3749.49M 4590.34M 4914.70M 5545.69M
Short term debt 1044.62M 45.78M 624.40M 31.00M 31.00M
Short long term debt 1029.90M 31.00M 604.95M 31.00M 31.00M
Short long term debt total 5423.87M 6162.36M 5796.65M 5796.18M 6137.14M
Other stockholder equity 4240.94M 3914.01M 3699.95M 3477.60M 3535.26M
Property plant equipment - - - 301.38M 343.42M
Total current assets 4166.04M 4629.03M 3263.92M 2606.14M 2611.33M
Net tangible assets - - - -4329.53M -5014.75M
Short term investments 1050.00M 580.00M 420.00M - 0.00M
Net receivables 830.75M 716.76M 705.79M 651.49M 563.36M
Long term debt 4328.35M 6077.64M 5107.99M 5693.34M 6018.94M
Inventory 416.96M 480.44M 597.04M 714.06M 1072.72M
Accounts payable 122.06M 77.87M 102.75M 90.76M 100.30M
Accumulated other comprehensive income -568.60M -947.67M -841.67M -1125.51M -400.36M
Common stock total equity - - - 0.01M 0.01M
Retained earnings total equity - - - 733.59M 830.23M
Non currrent assets other 102.28M 119.64M 240.75M 64.39M 40.81M
Non current assets total 7493.30M 7383.23M 8129.44M 8229.11M 9687.31M
Capital lease obligations 65.61M 53.72M 78.67M 87.78M 102.96M
Long term debt total - - - 5693.34M 6018.94M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -470.27M -508.19M -589.24M -1.04M 1068.18M
Change to liabilities - - - 141.68M 54.72M
Total cashflows from investing activities -1509.91M -508.19M - -446.23M -5212.14M
Net borrowings -781.00M 374.77M - -582.01M 3870.86M
Total cash from financing activities -873.38M 20.52M -305.25M -529.49M 3970.52M
Change to operating activities - - - 164.69M 54.45M
Net income -356.15M 560.12M 414.83M -224.06M -329.67M
Change in cash -1020.97M 906.55M 354.83M 290.03M -466.32M
Begin period cash flow 2412.86M 1506.31M 851.48M 591.45M 1057.77M
End period cash flow 1391.90M 2412.86M 1206.31M 881.48M 591.45M
Total cash from operating activities 1355.77M 1395.91M 1092.01M 1271.98M 778.51M
Depreciation 696.30M 660.07M 638.70M 629.47M 552.48M
Other cashflows from investing activities -122.83M -10.00M - -416.15M -5212.14M
Dividends paid - - - 98.02M 99.66M
Change to inventory -86.04M -45.54M -13.42M -49.64M -48.86M
Change to account receivables -106.28M -21.11M -51.88M -90.14M -92.73M
Sale purchase of stock -125.02M -311.43M -269.76M -0.05M -35.60M
Other cashflows from financing activities -75.22M -63.47M -50.95M 52.58M 5291.12M
Change to netincome - - - 139.12M 603.64M
Capital expenditures 209.75M 48.07M 23.96M 498.19M 45.53M
Change receivables - - - -90.14M -92.73M
Cash flows other operating - - - 725.54M 137.82M
Cash and cash equivalents changes - - - 296.26M -463.11M
Change in working capital 18.90M -76.72M -204.44M 9.90M -47.95M
Stock based compensation 291.13M 248.04M 226.84M 222.00M 189.01M
Other non cash items 1150.56M 212.72M 276.29M 926.92M 345.44M
Free cash flow 1146.02M 1347.84M 1068.05M 773.78M 732.98M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
JAZZ
Jazz Pharmaceuticals PLC		 4.92
2.14%		 234.66 16.83 11.12 3.40 3.32 3.95 11.24
NVO
Novo Nordisk A/S		 1.99
4.95%		 42.18 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 18.28
3.44%		 549.04 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -41.91
4.31%		 931.45 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Waterloo Exchange, Dublin, Ireland, D04 E5W7

353 1 634 7800

https://www.jazzpharma.com

2890

Name Title Year Born
Mr. Bruce C. Cozadd Co-Founder, Chairman & CEO 1964
Mr. Daniel N. Swisher Jr. Pres & COO 1963
Ms. Renee D. Gala Exec. VP & CFO 1972
Dr. Robert Iannone M.D. Exec. VP and Global Head of R&D 1967
Ms. Patricia Carr Sr. VP & Chief Accounting Officer 1971
Dr. Finbar Larkin Ph.D. Sr. VP of Technical Operations 1958
Ms. Andrea N. Flynn Ph.D. VP & Head of Investor Relations NA
Ms. Neena M. Patil J.D. Exec. VP & Chief Legal Officer 1975
Dr. George Christopher Eliades Ph.D. Sr. VP of Corp. Devel. & Chief Transformation Officer 1970
Ms. Heidi Manna Sr. VP & Chief HR Officer 1972

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…